publication . Article . 2018

Circulating Galectin‐3 Is Associated With Cardiometabolic Disease in the Community

Nayor, Matthew; Wang, Na; Larson, Martin G.; Vasan, Ramachandran S.; Levy, Daniel; Ho, Jennifer E.;
Open Access
  • Published: 13 Nov 2018 Journal: Journal of the American Heart Association, volume 5 (issn: 2047-9980, eissn: 2047-9980, Copyright policy)
  • Publisher: Ovid Technologies (Wolters Kluwer Health)
Abstract
Background Circulating Galectin‐3 (Gal‐3) concentrations are associated with an increased incidence of heart failure, atrial fibrillation, chronic kidney disease, and mortality. Recent evidence suggests that Gal‐3 may also be an important modulator of cardiometabolic traits such as adiposity, insulin resistance, and hyperglycemia. We examined the associations of blood Gal‐3 concentrations and cardiometabolic disease traits in the Framingham Heart Study. Methods and Results In cross‐sectional analyses of 2946 Framingham Heart Study participants (mean age 59 years, 55% women), higher Gal‐3 concentrations were associated with higher body mass index, waist circumfer...
Subjects
free text keywords: Cardiology and Cardiovascular Medicine, Metabolic syndrome, medicine.disease, medicine, Endocrinology, medicine.medical_specialty, Cardiology, Framingham Heart Study, Body mass index, Diabetes mellitus, Insulin resistance, Internal medicine, Hazard ratio, Odds ratio, Dyslipidemia, business.industry, business, Original Research, Epidemiology, obesity, prevention
Funded by
NIH| TRAINING PROGRAM IN CARDIOVASCULAR RESEARCH
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2T32HL007604-06
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
NIH| The Role of Galectin-3 in Cardiac Remodeling and Heart Failure
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 7K23HL116780-04
  • Funding stream: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
,
NIH| THE FRAMINGHAM HEART STUDY-268025195
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: N01HC025195-005
  • Funding stream: DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS
31 references, page 1 of 3

1 Baek J‐H, Kim S‐J, Kang HG, Lee H‐W, Kim J‐H, Hwang K‐A, Song J, Chun K‐H. Galectin‐3 activates PPARγ and supports white adipose tissue formation and high‐fat diet‐induced obesity. Endocrinology. 2015;156:147–156.25343273 [PubMed]

2 Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin‐3: an emerging all‐out player in metabolic disorders and their complications. Glycobiology. 2015;25:136–150.25303959 [OpenAIRE] [PubMed]

3 Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin‐3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249–1256.22939561 [OpenAIRE] [PubMed]

4 Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014;167:729–734.e1.24766984 [OpenAIRE] [PubMed]

5 O'Seaghdha CM, Hwang S‐J, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin‐3 precedes the development of CKD. J Am Soc Nephrol. 2013;24:1470–1477.23766533 [OpenAIRE] [PubMed]

6 Madrigal‐Matute J, Lindholt JS, Fernandez‐Garcia CE, Benito‐Martin A, Burillo E, Zalba G, Beloqui O, Llamas‐Granda P, Ortiz A, Egido J, Blanco‐Colio LM, Martin‐Ve ntura JL. Galectin‐3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014;3:e000785 doi: 10.1161/JAHA.114.000785.25095870 [OpenAIRE] [PubMed]

7 de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P. The fibrosis marker galectin‐3 and outcome in the general population. J Intern Med. 2012;272:55–64.22026577 [PubMed]

8 Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després J‐P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics‐2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.25520374 [PubMed]

9 Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, Kaptoge S, Whitlock G, Qiao Q, Lewington S, Di Angelantonio E, vander Hoorn S, Lawes CMM, Ali MK, Mozaffarian D, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group; Asia‐Pacific Cohort Studies Collaboration (APCSC), Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe (DECODE), Emerging Risk Factor Collaboration (ERFC), Prospective Studies Collaboration (PSC) . The age‐specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013;8:e65174.23935815 [OpenAIRE] [PubMed]

10 Kiwaki K, Novak CM, Hsu DK, Liu F‐T, Levine JA. Galectin‐3 stimulates preadipocyte proliferation and is up‐regulated in growing adipose tissue. Obesity (Silver Spring). 2007;15:32–39.17228029 [PubMed]

11 Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, Cooper D, Perretti M, Fantuzzi G. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin‐3 KO mice. PLoS One. 2013;8:e57915.23451284 [OpenAIRE] [PubMed]

12 Krautbauer S, Eisinger K, Hader Y, Buechler C. Free fatty acids and IL‐6 induce adipocyte galectin‐3 which is increased in white and brown adipose tissues of obese mice. Cytokine. 2014;69:263–271.25043674 [PubMed]

13 Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, Zdravkovic NS, Djukic AL, Arsenijevic NN, Lukic ML. Galectin‐3 deficiency accelerates high‐fat diet‐induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 2013;62:1932–1944.23349493 [OpenAIRE] [PubMed]

14 Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281–290.474565 [PubMed]

15 Christenson RH, Duh S‐H, Wu AHB, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P. Multi‐center determination of galectin‐3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43:683–690.20153309 [PubMed]

31 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2018

Circulating Galectin‐3 Is Associated With Cardiometabolic Disease in the Community

Nayor, Matthew; Wang, Na; Larson, Martin G.; Vasan, Ramachandran S.; Levy, Daniel; Ho, Jennifer E.;